XERIS BIOPHARMA HOLDINGS, INC. Jefferies Global Healthcare Conference in London - XERIS BIOPHARMA HOLDINGS INC
Financial Performance:
- Raised full-year 2024 revenue guidance to $395–$405 million (midpoint), representing 37% year-over-year growth.
- Q3 RecorLiv sales reached approximately $71 million, establishing a new, accelerated growth trajectory.
- Company has maintained profitability for over a year with gross margins of 88% and improving quarterly performance.
- Strong cash flow generation from profitable operations is now being evaluated for potential Business Development (M&A) activities.
- No specific mentions of debt levels, deferred revenue, or cash balance figures beyond confirming healthy balance sheet capacity.
Guidance and Future Outlook:
- Updated 2030 revenue outlook from $750 million to over $1 billion, driven by the growth of RecorLiv, Gvoke, and Cavays.
- RecorLiv trajectory has been accelerated; expected to reach $1 billion in sales in 3–4 years (previously projected for 2035).
- Full-year 2025 outlook remains positive with double-digit growth expected across all three core products (RecorLiv, Gvoke, Cavays).
- Targeting approval for the new product 8121 by 2030, with a potential peak sales range of $1–$3 billion if non-inferiority is achieved.
- Top-line data for the 8121 Phase 3 trial (Cornerstone) is targeted for release by end of 2028.
Business Segments and Product Lines:
- RecorLiv (Cushing's syndrome): Sales force doubled in January; experiencing robust growth driven by new clinical guidelines (ADA/ESAD) recommending cortisol testing for resistant diabetes/obesity; majority of new patients (>60%) are therapy-naïve; persistence is stable after the initial 3–4 month adjustment period.
- Gvoke (Hypoglycemia in diabetes): Re-entered a high single-to-low double-digit growth mode; targeting the 15 million eligible diabetic patients, though current penetration is <1%; focus on changing clinical practice to ensure patients have ready-to-use glucagon available.
- Cavays (Primary Periodic Paralysis): Previously flat, now on a growth curve following incremental investments in field personnel to identify the 4,000–5,000 patient population; emphasizes patient support and diagnosis education.
- 8121 (Hypothyroidism): Once-weekly subcutaneous product for patients failing oral levothyroxine absorption; Phase 3 initiation expected by end of year; designed as a non-inferiority trial ("Cornerstone") vs. Synthroid for 500 participants.
Market and Competitive Landscape:
- RecorLiv: Benefiting from guideline changes that expand the prescriber base from endocrinologists to primary care physicians; market dynamics show increased screening for hypercortisolism in patients with resistant comorbidities.
- Gvoke: Operating in a space with low current penetration (<1 million users vs. 15 million eligible); focus on overcoming physician inertia to prescribe rescue glucagon.
- 8121: Differentiated by addressing a 40-year innovation gap in thyroid treatment; real-world evidence suggests 25% of oral-treated patients are out of range (vs. 20% estimated), highlighting significant unmet need.
- Competition: RecorLiv faces prior authorization and medical necessity hurdles common to rare disease drugs, though payers currently show limited restrictions due to the niche patient population.
Risks and Challenges:
- Patient Persistence: RecorLiv faces attrition in the first 3–4 months due to cortisol withdrawal symptoms and the complexity of adjusting multiple comorbid medications (hypertension, diabetes).
- Market Access: Potential for payer restrictions (prior authorization, medical necessity) across all segments, though currently viewed as manageable due to the rare disease classification and clear clinical necessity.
- Clinical Execution: 8121 success relies on the non-inferiority endpoint; while superiority is a possibility, the strategy prioritizes a high-probability path to approval.
- Behavioral Change: Gvoke growth is contingent on shifting established clinician prescribing habits and office protocols.
Management Commentary and Tone:
- Management tone is highly confident, citing a "new growth trend" for RecorLiv and disciplined capital allocation.
- Emphasizes the synergy between commercial expansion and market demand shifts driven by updated clinical guidelines.
- Confident that the 8121 Phase 3 design aligns with FDA and KOL feedback, offering the highest probability of approval.
- Stated that BD is a priority now that cash flow is robust, but the company will remain disciplined to ensure execution on existing growth pillars first.
Analyst Questions and Answers:
- Sales Force ROI: Confirmed that the doubling of the sales force in January accelerated RecorLiv adoption significantly, with results visible in Q3 rather than the traditional 6–9 month lag.
- Guideline Impact: Clarified that new ADA/ESAD guidelines specifically direct primary care physicians to test for cortisol in resistant cases, broadening the addressable market beyond specialists.
- Payer Restrictions: Management noted that payers cannot easily block access due to the strict "medical necessity" criteria required for these rare disease indications.
- 8121 Pricing/Access: Pricing guidance deferred due to 2030 timeline; access strategy focuses on demonstrating failure of oral therapy in the chart to facilitate prior authorization.
- BD Strategy: Management clarified they have the balance sheet capacity for M&A but will prioritize assets that contribute to near-term (3–6 year) growth before 8121 becomes material.
Other Key Points:
- RecorLiv is on a trajectory to become a $1 billion product sooner than previously projected due to accelerated adoption.
- The company has successfully transitioned from a growth phase to a profitability phase, enabling strategic M&A considerations.
- Real-world evidence generation is a key pillar of the 8121 strategy to validate the unmet need among patients struggling with oral levothyroxine absorption.
- The "Cornerstone" study for 8121 is a comparative non-inferiority trial, with secondary endpoints measuring superiority and time-in-range.
- Company
- XERIS BIOPHARMA HOLDINGS INC
- Keywords
- XERIS BIOPHARMA HOLDINGS INC